



## Vaccine Development for SARS-CoV-2 and Zoonotic Diseases

Guest Editors:

### Dr. Abbas Khan

Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

### Prof. Dr. Dongqing Wei

Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

### Dr. Syed Shujait Ali

Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan

Deadline for manuscript submissions:

**closed (15 August 2023)**

### Message from the Guest Editors

Modern reverse vaccinology techniques enable the development of a targeted adaptive immune response. Numerous vaccines against human infections have been created using the epitope prediction technique. This involves the creation of a possible vaccine candidate against "Plasmodium vivax" based on the epitope (AMA-1). Such methods have been used, for example, to combat the Ebola virus, Marburg virus, Crimean–Congo hemorrhagic fever virus, and Mokola Rabies virus, which are all human pathogenic viruses. These vaccines are developed using the proteomes of different pathogens. Hence, this demonstrates the capability of proteome-based vaccines and their role in containing diseases. Therefore, the current issue will focus on the development of different vaccines for different diseases using proteins.

With these advancements, we welcome the submission of manuscripts on the following aspects:

- Protein-based vaccine design;
- Epitope platform development;
- Improving proteome-based vaccine prediction;
- Proteomics-based mRNA vaccine design;
- Identification and characterization of vaccine targets in the proteomes;
- Development and improvement of current peptide-based vaccines.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)